查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1771303

細胞重編程市場：產業趨勢及全球預測 - 依技術類型、細胞來源類型、應用類型和主要地區

Cell Reprogramming Market: Industry Trends and Global Forecasts - Distribution by Type of Technology, Type of Source Cell, Type of Application and Key Geographical Regions
出版日期: | 出版商: Roots Analysis | 英文 293 Pages | 商品交期: 最快1-2個工作天內

價格

全球細胞重編程市場：概覽

今年全球細胞重編程市場規模達 11.6億美元。預計預測期內，該市場的年複合成長率將達到 8%。

市場區隔與機會分析依下列參數劃分：

技術類型

  • 基於仙台病毒的重編程
  • mRNA重編程
  • 遊離型重編程
  • 其他重編程技術

細胞來源類型

  • 纖維母細胞
  • 週邊血單核細胞
  • 未指定的體細胞
  • 其他

應用類型

  • 研究
  • 治療

主要地區

  • 北美
  • 歐洲
  • 亞太地區及世界其他地區

全球細胞重編程市場：成長與趨勢

幹細胞研究進展多年來，細胞生物學和再生醫學的發展促成了各種基於幹細胞的療法的發現和發展。然而，細胞療法的開發和應用仍然存在挑戰，包括複雜的製造流程、健康細胞捐贈者的短缺以及與捐贈者-接受者單倍型錯配相關的擔憂。此外，將人類幹細胞用於研究目的也存在一些倫理障礙。因此，細胞重編程的概念應運而生，成為克服上述問題並發展安全有效的細胞治療介入的手段之一。

細胞重編程市場-IMG1

在生物技術領域的技術發展和再生醫學相關市場發展的推動下，全球許多研究小組目前開發創新的細胞重編程方法。此外，值得注意的是，各類新創公司和大學衍生公司已成為這一新興治療領域的先驅，預計將在未來幾年保持研究動力。

全球細胞重編程市場：關鍵洞察

本報告深入探討了全球細胞重編程市場的現狀，並識別了產業內的潛在成長機會。報告的主要調查結果包括：

  • 細胞重編程技術的進步為許多先進的治療和研究應用鋪平了道路，為行業和非行業服務提供商公司帶來了豐厚的商機。
  • 超過 30 家公司聲稱提供細胞重編程服務和產品。其中近 70%是小型企業（員工人數少於 50 人）。
  • 目前，大多數服務提供者（約 75%）使用遊離重編程技術提供 iPSC 生成服務，並聲稱能夠處理多種細胞類型。其次是提供直接重編程服務的公司（30%）。
  • 值得注意的是，大多數利害關係人聲稱使用遊離重編程方法來產生iPSC。其他流行的細胞重編程方法包括仙台病毒和基於mRNA的技術。
  • 許多公司聲稱使用多種技術來產生iPS細胞。例如Applied StemCell、Applied Biological Materials、Creative Bioarray、Lonza和Stemnovate。
  • 考慮到纖維母細胞的各種優勢，例如其易於獲取、增殖速度快和細胞穩健性，這些細胞在細胞重編程中得到了最大程度的利用（超過40%）。
  • 細胞重編程領域以眾多中小型公司為特徵，分佈在各個地區，參與者建立了多個設施來滿足客戶的需求。
  • 北美是領先的細胞重編程服務中心。超過55%參與細胞重編程的公司總部位於北美，其次是總部位於歐洲的公司（45%）。
細胞重編程市場-IMG2
  • 歐洲領先的機構包括英國、德國、丹麥、瑞士、法國、葡萄牙和瑞典。各利益相關者正積極擴展其產能，以豐富其細胞重編程服務組合，並在未來保持產業競爭力。
  • 過去達成的包括各種細胞類型的合作數量反映了人們對該領域日益成長的興趣。
  • 自2016年以來，合作活動以7%的年複合成長率成長。隨著對幹細胞的需求不斷成長，產業界和學術界的參與者很可能會就細胞重編程建立多種合作關係。
  • 過去幾年，現有企業和新進業者都已建立多項策略夥伴關係。大多數交易（超過30%）主要用於iPS細胞生成，並根據客戶需求進一步細分。
  • 許多公司已簽署多項細胞重編程協議。簽署四份或更多協議的公司包括Cellaria、BlueRock Therapeutics、FUJIFILM Cellular Dynamics和STEMCELL Technologies。
  • 過去幾年中，已有540多項臨床試驗啟動，評估各種類型的幹細胞療法，凸顯了對iPS細胞生成和直接重編程策略日益成長的需求。
  • 超過70%的臨床試驗由中小企業贊助，目的是探索幹細胞療法的潛力。
  • 一項針對300多家參與幹細胞療法開發的利害關係人的調查顯示，不同地區的公司可以成為細胞重編程服務提供者的策略夥伴。
  • 預計到2030年，該市場的年複合成長率將達到8%，機會可能遍布各種技術類型、應用領域和主要地區。
細胞重編程市場-IMG3
  • 目前，大部分服務收入來自包括遊離型重編程技術的計畫。
  • 預計到2030年，致力於遊離型重編程的計畫將占到總收入的40%以上，其次是基於仙台病毒的重編程計畫（30%）和mRNA重編程計畫（25%）的收入。

細胞重編程市場參與者

  • Allele Biotechnology
  • ALSTEM
  • Applied Biological Materials
  • Axol Bioscience
  • Creative Bioarray
  • DefiniGEN
  • FUJIFILM Cellular Dynamics
  • Lonza
  • Mogrify
  • REPROCELL
  • Stemnovate
  • Thermo Fisher Scientific

本報告調查全球細胞重編程市場，提供市場概述，以及依技術類型、細胞來源類型、應用類型和地區的趨勢，和參與市場的公司簡介。

目錄

第1章 簡介

第2章 執行摘要

第3章 簡介

  • 章節概述
  • 幹細胞概述
  • 細胞重編程簡介
  • 細胞重編程的應用
  • 主要成長與限制因素

第4章 當前市場格局

  • 章節概述
  • 細胞重編程服務與產品提供者：產業參與者列表
  • 細胞重編程服務與產品提供者：非產業參與者列表
  • 細胞重編程：相關產品提供者列表

章節5：公司競爭力分析

  • 章節概述
  • 假設和關鍵參數
  • 研究方法
  • 競爭分析：iPSC 產生服務與產品供應商
  • 競爭分析：直接重編程服務與產品供應商

第6章 公司簡介

  • 章節概述
  • Allele Biotechnology
  • ALSTEM
  • Applied Biological Materials
  • Axol Bioscience
  • Creative Bioarray
  • DefiniGEN
  • FUJIFILM Cellular Dynamics
  • Lonza
  • Mogrify
  • REPROCELL
  • Stemnovate
  • Thermo Fisher Scientific

第7章 案例研究：幹細胞療法研發中的臨床試驗活動

  • 章節概述
  • 研究範圍與研究方法
  • 幹細胞療法：臨床試驗分析

第8章 合作夥伴與合作

  • 章節概述
  • 研究範圍與研究方法
  • 細胞重編程服務與產品市場：合作夥伴與合作清單

第9章 合作夥伴潛力

  • 章節概述
  • 研究範圍與研究方法
  • 評分標準與關鍵假設
  • 幹細胞療法開發商：細胞重編程服務和產品提供者的有前途的合作夥伴
  • 幹細胞療法合約製造商：細胞重編程服務和產品提供者的有前途的合作夥伴

第10章 市場預測

  • 章節概述
  • 範圍與研究方法
  • 預測研究方法與關鍵假設
  • 2035年全球細胞重編程服務與市場佔有率及產品市場
    • 全球細胞重編程服務與產品市場（依技術類型）（2035）
    • 全球細胞重編程服務與產品市場（依細胞來源類型）（2035）
    • 全球細胞重編程服務與產品市場（依應用類型）（2035）
    • 全球細胞重編程服務與產品市場（依主要地區）（2035）

第11章 高層洞察

第12章 結論

第13章 附錄1：表格資料

第14章 附錄2：公司與組織清單

Product Code: RA100193

GLOBAL CELL REPROGRAMMING MARKET: OVERVIEW

As per Roots Analysis, the global cell reprogramming market valued at USD 1.16 billion in the current year is anticipated to grow at a CAGR of 8% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Technology

  • Sendai Virus-based Reprogramming
  • mRNA Reprogramming
  • Episomal Reprogramming
  • Other Reprogramming Technologies

Type of Source Cell

  • Fibroblasts
  • Peripheral Blood Mononuclear Cells
  • Unspecified Somatic Cells
  • Other Cells

Type of Application

  • Research
  • Therapeutic

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific and Rest of the World

GLOBAL CELL REPROGRAMMING MARKET: GROWTH AND TRENDS

Progress in stem cell biology and regenerative medicine over the years has led to the discovery and development of various stem cell-based therapies. However, prevalent challenges concerning the development and use of cell therapies persist, including complex production process, scarcity of healthy cell donors, and concerns associated with donor-recipient haplotype mismatch. Moreover, there are still several ethical barriers when it comes to using human stem cells for research purposes. Consequently, the concept of cell reprogramming has emerged as one of the means to overcome the aforementioned issues and develop safe and effective cell-based therapeutic interventions.

Cell Reprogramming Market - IMG1

Empowered by technical developments in the field of biotechnology and the market opportunity associated with regenerative medicine, a number of research groups across the world are presently developing innovative ways to reprogram cells. Further, it is worth noting that various start-ups and university spin-offs have emerged as pioneers in this emerging field of therapeutics and are anticipated to maintain the research momentum in the coming years as well.

GLOBAL CELL REPROGRAMMING MARKET: KEY INSIGHTS

The report delves into the current state of global cell reprogramming market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Advances in cell reprogramming have paved way for a plethora of advanced therapeutic and research applications, resulting in lucrative business opportunities for industry and non-industry service provider firms.
  • More than 30 companies claim to offer cell reprogramming services and products. Of these, close to 70% are small firms (having less than 50 employees).
  • Presently, the majority (~75%) of the service providers claim to offer iPSC generation services, using episomal reprogramming technologies, and are capable of working with various types of cells. This is followed by the companies offering direct reprogramming services (30%).
  • It is worth mentioning that majority of stakeholders claim to be using episomal reprogramming for generating iPSCs; other popular cell reprograming approaches include Sendai virus and mRNA-based technologies.
  • Numerous companies claim to use more than two technologies for the generation of iPSCs; examples include Applied StemCell, Applied Biological Materials, Creative Bioarray, Lonza and Stemnovate.
  • Given the various advantages associated with fibroblasts, such as easy availability, faster proliferation rate and cell robustness, these cells have found maximum (>40%) usage in cell reprogramming.
  • Featuring the presence of several small and mid-sized firms, the cell reprogramming landscape is well distributed across various regions; players have established multiple facilities to cater to the needs of their clients.
  • North America is a key services hub for cell reprogramming. More than 55% of companies engaged in cell reprogramming are headquartered in North America. This is followed by players based in Europe (45%).
Cell Reprogramming Market - IMG2
  • Prominent facilities within Europe include the UK, Germany, Denmark, Switzerland, France, Portugal and Sweden. Stakeholders are actively expanding their capabilities in order to enhance their respective cell reprogramming service portfolios and, thereby, maintain a competitive edge in this upcoming industry.
  • The rising interest in this field is reflected in the number of partnerships, involving a varied range of cell types, inked in the recent past; the maximum partnering activity has been observed in the US.
  • Since 2016, the partnership activity has increased at a CAGR of 7%; with the increasing demand for stem cells, both industry and academic players are likely to enter into multiple alliances for cell reprogramming.
  • Both established players and new entrants have forged several strategic partnerships in the recent past; majority (>30%) of the deals have primarily been inked for generations of iPSCs, which are further differentiated based on the client's requirement.
  • A number of companies have signed multiple deals for cell reprogramming; examples of the firms that have signed over four deals include Cellaria, BlueRock Therapeutics, FUJIFILM Cellular Dynamics and STEMCELL Technologies.
  • In the last few years, over 540 clinical trials, evaluating various types of stem cell therapies have been initiated; this highlights the rising demand for iPSC generation and direct reprogramming strategies.
  • >70% of these trials were / are being sponsored by small / mid-sized companies to exploit the potential of stem cell therapies to cater to the unmet need in this domain.
  • An evaluation of more than 300+ stakeholders engaged in the development of stem cell therapies reveals several likely strategic partners for cell reprogramming service providers, across different geographical regions.
  • The market is anticipated to grow at a CAGR of 8% till 2030, and the opportunity is likely to be distributed across different types of technologies, applications and key geographical regions.
Cell Reprogramming Market - IMG3
  • Presently, the majority share of service revenues is generated from projects involving episomal reprogramming technologies.
  • In 2030, episomal reprogramming focused projects are anticipated to contribute over 40% of the overall share; it is expected to be followed by revenues generated from projects involving Sendai virus-based reprogramming (30%) and mRNA (25%).

Example Players in the Cell Reprogramming Market

  • Allele Biotechnology
  • ALSTEM
  • Applied Biological Materials
  • Axol Bioscience
  • Creative Bioarray
  • DefiniGEN
  • FUJIFILM Cellular Dynamics
  • Lonza
  • Mogrify
  • REPROCELL
  • Stemnovate
  • Thermo Fisher Scientific

GLOBAL CELL REPROGRAMMING MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global cell reprogramming market, focusing on key market segments, including [A] type of technology, [B] type of source cell, [C] type of application and [D] key geographical regions.
  • Market Landscape: A comprehensive evaluation of cell reprogramming market, considering various parameters, such as [A] year of establishment, [B] company size, [C] geographical location, [D] location of manufacturing facilities, [E] type of service, [F] type of offering, [G] type of technology, [H] type of vector used, [I] source cell for iPSC generation, [J] target indication(s), [K] type of application and [L] additional service(s) offered.
  • Company Competitiveness Analysis: A comprehensive company competitive analysis of iPSC generation and direct reprogramming service providers, examining factors, such as [A] supplier strength and [B] service strength.
  • Company Profiles: In-depth profiles of the players that offer cell reprogramming services and products, focusing on [A] company overview, [B] financial information (if available), [C] details on cell reprogramming approaches, [D] types of cell(s) utilized and differentiated, [E] target indication(s), [F] other drug discovery services offered and [G] recent developments and an informed future outlook.
  • Clinical Trial Analysis: An insightful analysis more than 540 completed, ongoing and planned clinical studies of various stem cell therapies, based on several parameters, such as [A] trial registration year, [B] phase of development, [C] study design, [D] current trial status, [E] leading industry sponsors, [F] study focus, [G] type of stem cells, [H] target indication(s), [I] target therapeutic area(s), [J] enrolled patient population and [K] regional distribution of trials.
  • Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the cell reprogramming market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of stem cell, [D] target therapeutic area, [E] application, [F] most active players (in terms of the number of partnerships signed) and [G] geography.
  • Likely Partnership Opportunities: A detailed discussion on the stem cell therapy developers / manufacturers that are anticipated to partner with cell reprogramming service and product providers in the foreseen future, based on various relevant parameters, such as [A] company size, [B] type of cell (s), [C] indication counts and [D] existing partnership(s).

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
    • 1.2.1. Research Assumptions
    • 1.2.2. Project Methodology
    • 1.2.3. Forecast Methodology
    • 1.2.4. Robust Quality Control
    • 1.2.5. Key Considerations
      • 1.2.5.1. Demographics
      • 1.2.5.2. Economic Factors
      • 1.2.5.3. Government Regulations
      • 1.2.5.4. Supply Chain
      • 1.2.5.5. COVID Impact / Related Factors
      • 1.2.5.6. Market Access
      • 1.2.5.7. Healthcare Policies
      • 1.2.5.8. Industry Consolidation
  • 1.3 Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Stem Cells
    • 3.2.1. Classification of Stem Cells
      • 3.2.1.1. Based on Source of Stem Cell
      • 3.2.1.2. Based on Origin of Stem Cell
      • 3.2.1.3. Based on Potency of Stem Cell
    • 3.2.2. Routes of Administration of Stem Cell Therapies
    • 3.2.3. Applications of Stem Cell Therapies
  • 3.3. Introduction to Cell Reprogramming
    • 3.3.1. Cell Reprogramming Approaches and Affiliated Technologies
  • 3.4. Applications of Cell Reprogramming
  • 3.5. Key Growth Drivers and Constraints

4. CURRENT MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Cell Reprogramming Service and Product Providers: List of Industry Players
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Geographical Location
    • 4.2.4. Analysis by Location of Stem Cell Research Facilities
    • 4.2.5. Analysis by Type of Service
    • 4.2.6. Analysis by Type of Technology
    • 4.2.7. Analysis by Target Indication
    • 4.2.8. Analysis by Source Cell
    • 4.2.9. Analysis by Application Area
    • 4.2.10. Analysis by Additional Service(s) Offered
    • 4.2.11. Analysis by Type of Offering
  • 4.3. Cell Reprogramming Service and Product Providers: List of Non-Industry Players
    • 4.3.1. Analysis by Geographical Location
    • 4.3.2. Analysis by Type of Technology Used
    • 4.3.3. Analysis by Source Cell for iPSC Generation
    • 4.3.4. Analysis by Type of Offering
  • 4.4. Cell Reprogramming: List of Affiliated Products Providers

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Assumptions and Key Parameters
  • 5.3. Methodology
  • 5.4. Competitiveness Analysis: iPSC Generation Service and Product Providers
  • 5.5. Competitiveness Analysis: Direct Reprogramming Service and Product Providers

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Allele Biotechnology
    • 6.2.1. Company Overview
    • 6.2.2. Recent Developments and Future Outlook
  • 6.3. ALSTEM
    • 6.3.1. Company Overview
    • 6.3.2. Recent Developments and Future Outlook
  • 6.4. Applied Biological Materials
    • 6.4.1. Company Overview
    • 6.4.2. Recent Developments and Future Outlook
  • 6.5. Axol Bioscience
    • 6.5.1. Company Overview
    • 6.5.2. Recent Developments and Future Outlook
  • 6.6. Creative Bioarray
    • 6.6.1. Company Overview
      • 6.6.1.1. Recent Developments and Future Outlook
  • 6.7. DefiniGEN
    • 6.7.1. Company Overview
    • 6.7.2. Recent Developments and Future Outlook
  • 6.8. FUJIFILM Cellular Dynamics International
    • 6.8.1. Company Overview
    • 6.8.2. Recent Developments and Future Outlook
  • 6.9. Lonza
    • 6.9.1. Company Overview
    • 6.9.2. Recent Developments and Future Outlook
  • 6.10. Mogrify
    • 6.10.1. Company Overview
    • 6.10.2. Recent Developments and Future Outlook
  • 6.11. REPROCELL
    • 6.11.1. Company Overview
      • 6.11.1.1. Recent Developments and Future Outlook
  • 6.12. Stemnovate
    • 6.12.1. Company Overview
    • 6.12.2. Recent Developments and Future Outlook
  • 6.14. Thermo fisher Scientific
    • 6.14.1. Company Overview
      • 6.14.1.1. Recent Developments and Future Outlook

7. CASE STUDY: CLINICAL TRIAL ACTIVITY IN STEM CELL THERAPY DEVELOPMENT

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Stem Cell Therapies: Clinical Trial Analysis
    • 7.3.1. Analysis by Trial Registration Year
    • 7.3.2. Analysis by Trial Phase
    • 7.3.3. Analysis by Number of Patients Enrolled by Trial Registration Year
    • 7.3.4. Analysis by Study Design
    • 7.3.5. Analysis by Trial Recruitment Status
    • 7.3.6. Analysis by Sponsor / Collaborator
    • 7.3.7. Leading Industry Sponsors: Analysis by Number of Registered Trials
    • 7.3.8. Analysis by Trial Focus
    • 7.3.9. Analysis by Type of Stem Cell
    • 7.3.10. Analysis by Therapeutic Area
    • 7.3.11. Analysis by Type of Stem Cell and Therapeutic Area
    • 7.3.12. Geographical Analysis by Number of Clinical Trials
    • 7.3.13. Geographical Analysis by Trial Recruitment Status
    • 7.3.14. Geographical Analysis by Enrolled Patient Population

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Cell Reprogramming Services and Products Market: List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Year of Partnership and Type of Partner
    • 8.3.4. Analysis by Type of Partnership and Type of Partner
    • 8.3.5. Analysis by Type of Stem Cell
    • 8.3.6. Analysis by Target Therapeutic Area
    • 8.3.7. Analysis by Application
    • 8.3.8. Most Active Players: Analysis by Number of Partnerships
    • 8.3.9. Regional Analysis
    • 8.3.10. Intercontinental and Intracontinental Agreements

9. LIKELY PARTNERSHIP OPPORTUNITIES

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Scoring Criteria and Key Assumptions
  • 9.4. Stem Cell Therapy Developers: Likely Partners for Cell Reprogramming Service and Product Providers
    • 9.4.1. Likely Partners for Cell Reprogramming Service and Product Providers in North America
    • 9.4.2. Likely Partners for Cell Reprogramming Service and Product Providers in Europe
    • 9.4.3. Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World
  • 9.5. Stem Cell Therapy Contract Manufacturers: Likely Partners for Cell Reprogramming Service and Product Providers
    • 9.5.1. Likely Partners for Cell Reprogramming Service and Product Providers in North America
    • 9.5.2. Likely Partners for Cell Reprogramming Service and Product Providers in Europe
    • 9.5.3. Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World

10. MARKET FORECAST

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Forecast Methodology and Key Assumptions
  • 10.4. Global Cell Reprogramming Services and Products Market, Till 2035
    • 10.4.1. Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, Till 2035
      • 10.4.1.1. Cell Reprogramming Services and Products Market for Episomal Reprogramming, Till 2035
      • 10.4.1.2. Cell Reprogramming Services and Products Market for mRNA Reprogramming, Till 2035
      • 10.4.1.3. Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, Till 2035
      • 10.4.1.4. Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, Till 2035
    • 10.4.2. Global Cell Reprogramming Services and Products Market: Distribution by Type of Source Cell, Till 2035
      • 10.4.2.1. Cell Reprogramming Services and Products Market for Fibroblasts, Till 2035
      • 10.4.2.2. Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, Till 2035
      • 10.4.2.3. Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, Till 2035
      • 10.4.2.4. Cell Reprogramming Services and Products Market for Other Cells, Till 2035
    • 10.4.3. Global Cell Reprogramming Services and Products Market: Distribution by Type of Application, Till 2035
      • 10.4.3.1. Cell Reprogramming Services and Products Market for Research, Till 2035
      • 10.4.3.2. Cell Reprogramming Services and Products Market for Therapeutic, Till 2035
    • 10.4.4. Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, Till 2035
      • 10.4.4.1. Cell Reprogramming Services and Products Market in North America, Till 2035
      • 10.4.4.2. Cell Reprogramming Services and Products Market in Europe, Till 2035
      • 10.4.4.3. Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, Till 2035

11. EXECUTIVE INSIGHTS

  • 11.1. Chapter Overview
  • 11.2. Company A
    • 11.2.1. Company Snapshot
    • 11.2.2. Interview Transcript: Co-Founder and Chief Executive Officer
  • 11.3. Company B
    • 11.3.1. Company Snapshot
    • 11.3.2. Interview Transcript: Chief Scientific Officer

12. CONCLUDING REMARKS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 3.1 Differences between Stem Cell Therapies and Other Biologics
  • Table 4.1 Cell Reprogramming Services and Products: List of Industry Players
  • Table 4.2 Cell Reprogramming Services and Products: List of Non-Industry Players
  • Table 4.3 Cell Reprogramming Services and Products: List of Affiliated Product Providers
  • Table 6.1 Cell Reprogramming Service and Product Providers: List of Profiled Companies
  • Table 6.2 ALSTEM: Company Snapshot
  • Table 6.3 ALSTEM: Recent Developments and Future Outlook
  • Table 6.4 Applied Biological Materials: Company Snapshot
  • Table 6.5 Applied Biological Materials: Recent Developments and Future Outlook
  • Table 6.6 Axol Bioscience: Company Snapshot
  • Table 6.7 Axol Bioscience: Recent Developments and Future Outlook
  • Table 6.8 Creative Bioarray: Company Snapshot
  • Table 6.9 Creative Bioarray: Recent Developments and Future Outlook
  • Table 6.10 DefiniGEN: Company Snapshot
  • Table 6.11 DefiniGEN: Recent Developments and Future Outlook
  • Table 6.12 FUJIFILM Cellular Dynamics International: Company Snapshot
  • Table 6.13 FUJIFILM Cellular Dynamics International: Recent Developments and Future Outlook
  • Table 6.14 Lonza: Company Snapshot
  • Table 6.15 Lonza: Recent Developments and Future Outlook
  • Table 6.16 Mogrify: Company Snapshot
  • Table 6.17 Mogrify: Recent Developments and Future Outlook
  • Table 6.18 REPROCELL: Company Snapshot
  • Table 6.19 REPROCELL: Recent Developments and Future Outlook
  • Table 6.20 Stemnovate: Company Snapshot
  • Table 6.21 Stemnovate: Recent Developments and Future Outlook
  • Table 6.22 Thermo Fisher Scientific: Company Snapshot
  • Table 6.23 Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 7.1 Cell Reprogramming Services: List of Partnerships and Collaborations
  • Table 9.1 Likely Partners for Cell Reprogramming Service and Product Providers in North America
  • Table 9.2 Likely Partners for Cell Reprogramming Service and Product Providers in Europe
  • Table 9.3 Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World
  • Table 9.4 Likely Partners for Cell Reprogramming Service and Product Providers in North America
  • Table 9.5 Likely Partners for Cell Reprogramming Service and Product Providers in Europe
  • Table 9.6 Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World
  • Table 11.1 Asgard Therapeutics: Company Snapshot
  • Table 11.2 Phenocell: Company Snapshot
  • Table 13.1 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Year of Establishment
  • Table 13.2 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Company Size
  • Table 13.3 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Geographical Location
  • Table 13.4 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Location of Manufacturing Facilities
  • Table 13.5 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Service
  • Table 13.6 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Offering
  • Table 13.7 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology
  • Table 13.8 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology and Year of Establishment
  • Table 13.9 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Vector Used
  • Table 13.10 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation
  • Table 13.11 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Source Cell for iPSC Generation and company size
  • Table 13.12 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Target Indication
  • Table 13.13 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of directly reprogrammed cell
  • Table 13.14 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Application
  • Table 13.15 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
  • Table 13.16 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Geographical Location
  • Table 13.17 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Technology
  • Table 13.18 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Vector Used
  • Table 13.19 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Source Cell for iPSC Generation
  • Table 13.20 Clinical Trial Analysis: Distribution by Trial Status
  • Table 13.21 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Since Pre-2010
  • Table 13.22 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 13.23 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Since 2011
  • Table 13.24 Clinical Trial Analysis: Distribution by Study Design
  • Table 13.25 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
  • Table 13.26 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 13.27 Clinical Trial Analysis: Leading Industry Players
  • Table 13.28 Clinical Trial Analysis: Analysis by Type of Stem Cell
  • Table 13.29 Clinical Trial Analysis: Cumulative Distribution by Type of Stem Cell and Trial Registration Year
  • Table 13.30 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Table 13.31 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
  • Table 13.32 Clinical Trial Analysis: Distribution by Patient Enrollment and Therapeutic Area
  • Table 13.33 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollment (in thousands) for Popular Therapeutic Areas
  • Table 13.34 Clinical Trial Analysis: Distribution by Type of Stem Cell and Therapeutic Area
  • Table 13.35 Clinical Trial Analysis: Geographical Distribution by Number of Trials
  • Table 13.36 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
  • Table 13.37 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient
  • Table 13.38 Partnerships and Collaborations: Analysis by Year of Partnership
  • Table 13.39 Partnerships and Collaborations: Analysis by Type of Partnership
  • Table 13.40 Partnerships and Collaborations: Analysis by Year of Partnership and Type of Partner
  • Table 13.41 Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
  • Table 13.42 Partnerships and Collaborations: Analysis by Type of Stem Cell
  • Table 13.43 Partnerships and Collaborations: Analysis by Target Therapeutic Area
  • Table 13.44 Partnerships and Collaborations: Analysis by Application
  • Table 13.45 Most Active Players: Distribution by Number of Partnerships
  • Table 13.46 Partnerships and Collaborations: Regional Analysis
  • Table 13.47 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 13.48 Global Cell Reprogramming Services and Products Market, Till 2035 (USD Million)
  • Table 13.49 Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, Till 2035
  • Table 13.50 Cell Reprogramming Services and Products Market for Episomal Reprogramming, Till 2035 (USD Million)
  • Table 13.51 Cell Reprogramming Services and Products Market for mRNA Reprogramming, Till 2035 (USD Million)
  • Table 13.52 Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, Till 2035 (USD Million)
  • Table 13.53 Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, Till 2035 (USD Million)
  • Table 13.54 Global Cell Reprogramming Services and Products Market: Distribution by Source Cell for iPSC Generation, Till 2035
  • Table 13.55 Cell Reprogramming Services and Products Market for Fibroblasts, Till 2035 (USD Million)
  • Table 13.56 Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, Till 2035 (USD Million)
  • Table 13.57 Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, Till 2035 (USD Million)
  • Table 13.58 Cell Reprogramming Services and Products Market for Other Cells, Till 2035 (USD Million)
  • Table 13.59 Global Cell Reprogramming Services and Products Market: Distribution by Application, Till 2035
  • Table 13.60 Cell Reprogramming Services and Products Market for Research, Till 2035 (USD Million)
  • Table 13.61 Cell Reprogramming Services and Products Market for Therapeutic Use, Till 2035 (USD Million)
  • Table 13.62 Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, Till 2035
  • Table 13.63 Cell Reprogramming Services and Products Market in North America, Till 2035 (USD Million)
  • Table 13.64 Cell Reprogramming Services and Products Market in Europe, Till 2035 (USD Million)
  • Table 13.65 Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, Till 2035 (USD Million)

List of Figures

  • Figure 3.1 Cellular Lineages used for Isolation of Stem Cells
  • Figure 3.2 Steps Involved in the Development and Administration of Stem Cells
  • Figure 3.3 Classification of Stem Cells
  • Figure 3.4 Classification based on Source of Stem Cell
  • Figure 3.5 Differences between Allogeneic and Autologous Stem Cell Therapies
  • Figure 3.6 Classification of Stem Cells based on Origin
  • Figure 3.7 Classification of Adult Stem Cells
  • Figure 3.8 Classification based on Potency of Stem Cell
  • Figure 3.9 Key Application Areas for Stem Cell Therapies
  • Figure 3.10 Potential Applications of Cell Reprogramming
  • Figure 3.11 Key Growth Drivers and Constraints to Cell Reprogramming
  • Figure 4.1 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Year of Establishment
  • Figure 4.2 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Company Size
  • Figure 4.3 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Geographical Location
  • Figure 4.4 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Location of Manufacturing Facilities
  • Figure 4.5 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Service
  • Figure 4.6 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Offering
  • Figure 4.7 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology
  • Figure 4.8 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology and Year of Establishment
  • Figure 4.9 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Vector Used
  • Figure 4.10 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation
  • Figure 4.11 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation and Company size
  • Figure 4.12 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Target Indication
  • Figure 4.13 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Directly Reprogrammed cells
  • Figure 4.14 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Application
  • Figure 4.15 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
  • Figure 4.16 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Geographical Location
  • Figure 4.17 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Technology
  • Figure 4.18 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Vector Used
  • Figure 4.19 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Source Cell for iPSC Generation
  • Figure 5.1 Competitiveness Analysis of iPSCs Generation Service and Product Providers
  • Figure 5.2 Competitiveness Analysis of Direct Reprogramming Service and Product Providers
  • Figure 7.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 7.2 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 7.3 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Since Pre-2010
  • Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 7.5 Clinical Trial Analysis: Distribution by Number of Patients Enrolled and Trial Registration Year, Since 2011
  • Figure 7.6 Clinical Trial Analysis: Distribution by Study Design
  • Figure 7.7 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
  • Figure 7.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 7.9 Clinical Trial Analysis: Leading Industry Players
  • Figure 7.10 Clinical Trial Analysis: Distribution by Focus Area
  • Figure 7.11 Clinical Trial Analysis: Distribution by Type of Stem Cell
  • Figure 7.12 Clinical Trial Analysis: Cumulative Distribution by Type of Stem Cell and Trial Registration Year
  • Figure 7.13 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Figure 7.14 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
  • Figure 7.15 Clinical Trial Analysis: Distribution by Patient Enrollment and Therapeutic Area
  • Figure 7.16 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollment (in thousands) for Popular Therapeutic Areas
  • Figure 7.17 Clinical Trial Analysis: Distribution by Type of Stem Cell and Therapeutic Area
  • Figure 7.18 Clinical Trial Analysis: Geographical Distribution by Number of Trials
  • Figure 7.19 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
  • Figure 7.20 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
  • Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 8.5 Partnerships and Collaborations: Distribution by Type of Stem Cell
  • Figure 8.6 Partnerships and Collaborations: Distribution by Target Therapeutic Area
  • Figure 8.7 Partnerships and Collaborations: Distribution by Application
  • Figure 8.8 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.9 Partnerships and Collaborations: Regional Analysis
  • Figure 8.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreement
  • Figure 10.1 Global Cell Reprogramming Services and Products Market, Till 2035 (USD Million)
  • Figure 10.2 Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, Till 2035
  • Figure 10.3 Cell Reprogramming Services and Products Market for Episomal Reprogramming, Till 2035 (USD Million)
  • Figure 10.4 Cell Reprogramming Services and Products Market for mRNA Reprogramming, Till 2035 (USD Million)
  • Figure 10.5 Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, Till 2035 (USD Million)
  • Figure 10.6 Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, Till 2035 (USD Million)
  • Figure 10.7 Global Cell Reprogramming Services and Products Market: Distribution by Source Cell for iPSC Generation, Till 2035
  • Figure 10.8 Cell Reprogramming Services and Products Market for Fibroblasts, Till 2035 (USD Million)
  • Figure 10.9 Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, Till 2035 (USD Million)
  • Figure 10.10 Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, Till 2035 (USD Million)
  • Figure 10.11 Cell Reprogramming Services and Products Market for Other Cells, Till 2035 (USD Million)
  • Figure 10.12 Global Cell Reprogramming Services and Products Market: Distribution by Application, Till 2035
  • Figure 10.13 Cell Reprogramming Services and Products Market for Research, Till 2035 (USD Million)
  • Figure 10.14 Cell Reprogramming Services and Products Market for Therapeutic Use, Till 2035 (USD Million)
  • Figure 10.15 Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, Till 2035
  • Figure 10.16 Cell Reprogramming Services and Products Market in North America, Till 2035 (USD Million)
  • Figure 10.17 Cell Reprogramming Services and Products Market in Europe, Till 2035 (USD Million)
  • Figure 10.18 Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, Till 2035 (USD Million)